UCB’s management has set the ambitious goal to develop and produce medicines for people with severe diseases in the most environmentally sustainable way possible. Inspired by the Paris agreement, UCB decided to accelerate the implementation of its Environmental Strategy (also called Green Strategy) by setting the ambitious, absolute target to reach a waste reduction by 25% by 2030.
UCB Belgium has been reducing the waste generated at its Belgian sites continuously since 2005. Key to its success is the high quality separation at the source of the waste generated by UCB’s activities. This allows the company to maintain over 60 different waste streams, enabling a maximum of waste that is reused or recycled.
One success story is the transformation of Polyethylene terephthalate (PET) waste into 3D printing filaments by a partner company. The filaments return to UCB as resource for the companies’ 3D-printers that fabricate new laboratory supplies and objects.
UCB’s ambitions go beyond the waste generated at its site, and the company is also focusing on reducing the drug and packaging waste for our patients. UCB received the 2019 Pharmapack Europe Eco-Design Award for the improved design of the Cimzia 200mg/Vial Lyophilized Powder Pack.
The success of today is built on the motivation of many people in our Green Teams, in the HSE department and all personnel actively working on making the UCB Green Strategy a reality. Multiple examples show how people turned ideas into concrete action and best practices.
UCB is a global biopharma company focusing on creating value for people living with severe diseases in immunology and neurology. UCB’s headquarters are in Brussels and the Belgian site of Braine-l’Alleud is one of the Group’s principal R&D and production entities.